IP
SUPN icon

Isthmus Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Isthmus Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,110
Closed -$1.71M – 206
2024
Q1 		$1.71M Sell
50,110
-25,651
-34% -$764K 0.19% 109
2023
Q4 		$2.19M Buy
75,761
+11,289
+18% +$299K 0.29% 79
2023
Q3 		$1.78M Buy
64,472
+1,858
+3% +$56.6K 0.26% 89
2023
Q2 		$1.88M Sell
62,614
-292
-0.5% -$10.2K 0.26% 86
2023
Q1 		$2.28M Buy
62,906
+693
+1% +$26.6K 0.32% 64
2022
Q4 		$2.22M Buy
62,213
+159
+0.3% +$5.53K 0.33% 60
2022
Q3 		$2.1M Buy
62,054
+2,700
+5% +$87.9K 0.36% 57
2022
Q2 		$1.72M Buy
59,354
+1,791
+3% +$51.3K 0.32% 70
2022
Q1 		$1.86M Buy
57,563
+3,107
+6% +$95.3K 0.31% 70
2021
Q4 		$1.59M Buy
54,456
+947
+2% +$28.7K 0.27% 88
2021
Q3 		$1.43M Buy
53,509
+2,528
+5% +$67.9K 0.26% 91
2021
Q2 		$1.57M Buy
50,981
+1,000
+2% +$30.7K 0.28% 84
2021
Q1 		$1.31M Buy
49,981
+942
+2% +$26.3K 0.24% 98
2020
Q4 		$1.23M Sell
49,039
-236
-0.5% -$5.08K 0.25% 92
2020
Q3 		$1.03M Buy
49,275
+5,018
+11% +$114K 0.24% 84
2020
Q2 		$1.05M Buy
44,257
+4,179
+10% +$92.3K 0.26% 79
2020
Q1 		$721K Sell
40,078
-1,126
-3% -$23.7K 0.22% 83
2019
Q4 		$977K Buy
41,204
+2,405
+6% +$58.4K 0.22% 94
2019
Q3 		$1.07M Buy
38,799
+7,635
+24% +$226K 0.25% 86
2019
Q2 		$1.03M Buy
31,164
+9,196
+42% +$315K 0.25% 83
2019
Q1 		$1.36M Sell
21,968
-5,468
-20% -$203K 0.33% 56
2018
Q4 		$911K Buy
27,436
+2,736
+11% +$118K 0.27% 80
2018
Q3 		$1.24M Buy
24,700
+118
+0.5% +$5.83K 0.31% 53
2018
Q2 		$1.47M Sell
24,582
-743
-3% -$38.5K 0.38% 48
2018
Q1 		$1.16M Sell
25,325
-50
-0.2% -$2.09K 0.31% 52
2017
Q4 		$1.01M Sell
25,375
-87
-0.3% -$3.44K 0.28% 62
2017
Q3 		$1.02M Sell
25,462
-1,078
-4% -$46.7K 0.29% 61
2017
Q2 		$1.14M Sell
26,540
-421
-2% -$15K 0.33% 49
2017
Q1 		$844K Buy
+26,961
New +$723K 0.25% 72

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Isthmus Partners's SUPN Position: Q2 2024 in Review

Isthmus Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 50,110 shares — an estimated $1.71M sold.

Isthmus Partners first reported a position in SUPN in Q1 2017 and held it in 29 quarters. The position peaked at $2.28M in Q1 2023. 244 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.

  • Isthmus Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Isthmus Partners sold 50,110 Supernus Pharmaceuticals shares in Q2 2024, an estimated $1.71M.
  • Isthmus Partners first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 29 quarters.
  • Isthmus Partners's Supernus Pharmaceuticals position peaked at $2.28M in Q1 2023.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.

Based on Isthmus Partners's 13F filing for Q2 2024, filed 6 Aug 2024.